AmSurg stock rated at ‘buy’

Analysts from Cantor Fitzgerald have rated AmSurg stock at “buy,” according to an Analyst Ratings report.

Advertisement

Cantor Fitzgerald set the company’s shares at a price target of $67. AmSurg has a market cap of $2.98 billion.

More articles on transactions and valuation issues:
How much does it cost to build an outpatient surgery center?
SCA closes secondary public offering of common stock
AmSurg acquires Halifax Anesthesiology Associates

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

  • In December 2025, HHS, alongside the Labor and Treasury departments, proposed significant updates to healthcare price transparency rules.  Comments for…

  • Legislators in Tennessee have delayed a vote on a bill that would loosen the state’s certificate-of-need laws, the TimesNews reported…

Advertisement

Comments are closed.